TREAT TO TARGET EARLY RHEUMATOID ARTHRITIS CLINIC: HIGH RATES OF REMISSION AND LOW DISEASE ACTIVITY ON TREATMENT WITH CONVENTIONAL DISEASE MODIFYING DRUGS

被引：0
|
作者：
Semenova, O. [1 ]
Thompson, H. [1 ]
Kallankara, S. [1 ]
Olabambo, O. [1 ]
Patel, Y. [1 ,2 ]
Baguley, E. [1 ]
机构：
[1] Hull Royal Infirm, Kingston Upon Hull HU3 2JZ, N Humberside, England
[2] Univ Hull, Hull & York Med Sch, Kingston Upon Hull HU6 7RX, N Humberside, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷
关键词：
D O I：
10.1136/annrheumdis-2012-eular.2114
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：205 / 206
页数：2
相关论文
共 50 条
  • [1] Treat to Target, Remission and Low Disease Activity in the Treatment of Rheumatoid Arthritis
    Martin Jan Bergman
    [J]. Current Treatment Options in Rheumatology, 2020, 6 : 260 - 267
  • [2] Treat to Target, Remission and Low Disease Activity in the Treatment of Rheumatoid Arthritis
    Bergman, Martin Jan
    [J]. CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY, 2020, 6 (03) : 260 - 267
  • [3] TREAT TO TARGET IN EARLY RHEUMATOID ARTHRITIS CLINIC (EAC): LOW RADIOLOGICAL PROGRESSION AND GOOD FUNCTIONAL OUTCOMES ON CONVENTIONAL DISEASE MODIFYING DRUGS (DMARDS)
    Semenova, O.
    Thompson, H.
    Kallankara, S.
    Ogunbambi, O.
    Patel, Y.
    Baguley, E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 250 - 250
  • [4] Conventional disease-modifying antirheumatic drugs to treat rheumatoid arthritis
    Rath, T.
    Sander, O.
    Rubbert, A.
    [J]. DRUG DEVELOPMENT RESEARCH, 2011, 72 (08) : 657 - 663
  • [5] LOW DISEASE ACTIVITY OR DAS-REMISSION AS TREATMENT TARGET IN EARLY RHEUMATOID ARTHRITIS PATIENTS
    Akdemir, G.
    Markusse, I. M.
    Schouffoer, A. A.
    de Sonnaville, P. B.
    Grillet, B. A.
    Kerstens, P. J.
    Lems, W. F.
    Huizinga, T. W.
    Allaart, C. F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 454 - 454
  • [6] FREQUENCY AND PREDICTORS OF SUSTAINED REMISSION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING DRUGS
    Zanframundo, G.
    Bugatti, S.
    Manzo, A.
    Benaglio, F.
    Sakellariou, G.
    Montecucco, C.
    Caporali, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 277 - 278
  • [7] Long-Term High Remission Rates and Distinct Trajectories of Disease Activity Following the Implementation of Treat-to-Target in Early Rheumatoid Arthritis
    Versteeg, Letty G. A.
    Steunebrink, Laura M. M.
    Kuper, Ina H.
    ten Klooster, Peter M.
    van der Bijl, Arie E.
    Vonkeman, Harald E.
    van de laar, Mart A. F. J.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [8] TREAT TO TARGET IN EARLY RHEUMATOID ARTHRITIS CLINIC (EAC): REMISSION RATES ON COMBINATION OF LEFLUNOMIDE, HYDROXYCHLOROQUINE AND METHOTREXATE
    Semenova, O.
    Thompson, H.
    Kallankara, S.
    Ogunbambi, O.
    Patel, Y.
    Baguley, E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 896 - 896
  • [9] APPLICATION OF TREAT TO TARGET AND IMPACT OF SUSTAINED LOW DISEASE ACTIVITY OR REMISSION ON FUNCTION IN RHEUMATOID ARTHRITIS PATIENTS
    Bessette, Louis
    Keystone, Ed
    Rahman, Proton
    Anderson, Keltie
    Rampakakis, Emmanouil
    Lehman, Allen J.
    Rachich, Meagan
    Nantel, Francois
    Asin-Milan, Odalis
    [J]. INTERNAL MEDICINE JOURNAL, 2020, 50 : 9 - 9
  • [10] APPLICATION OF TREAT TO TARGET AND IMPACT OF SUSTAINED LOW DISEASE ACTIVITY OR REMISSION ON FUNCTION IN RHEUMATOID ARTHRITIS PATIENTS
    Bessette, Louis
    Keystone, Edward
    Rahman, Proton
    Anderson, Keltie
    Rampakakis, Emmanouil
    Lehman, Allen J.
    Rachich, Meagan
    Nantel, Francois
    Asin-Milan, Odalis
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 27 - 27
12345